52 completed, 7 recruiting, 6 terminated, 3 unknown. 19 Not applicable, 17 Phase 3, 16 Phase 2, 11 Phase 1, 9 Phase 4.
Follow Laboratoires Thea: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution Administration Articaine (CYKLX), Vehicle - Healthy Cornea | Phase 4 | Not yet recruiting | Laboratoires Thea | 165 | 2027-01-01 | 2026-09-24 |
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695 - Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | Recruiting | Laboratoires Thea | 120 | 2026-03-24 | 2026-04-22 |
| Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression T10430 lower dose, T10430 middle dose, T10430 higher dose - Myopia | Phase 2 | Recruiting | Laboratoires Thea | 200 | 2026-01-21 | 2026-04-13 |
| A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study Cyclosporin - Dry Eye Disease (DED) | Completed | Laboratoires Thea | 25 | 2026-01-20 | 2026-08-14 | |
| Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery Cosmetic: Blephaderm - Eyelid; Wound | Recruiting | Laboratoires Thea | 30 | 2025-10-30 | 2026-05-04 | |
| New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye T2769 - Dry Eye Disease (DED) | Not applicable | Completed | Laboratoires Thea | 30 | 2025-10-21 | 2026-08-17 |
| Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® Adherence to Glaucoma Therapy | Recruiting | Laboratoires Thea | 200 | 2025-09-19 | 2026-08-17 | |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease T2769 - Dry Eye Disease (DED) | Completed | Laboratoires Thea | 30 | 2025-01-27 | 2025-09-25 | |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. T2769, Hylo-Forte® - Dry Eye Syndrome | Not applicable | Completed | Laboratoires Thea | 74 | 2024-09-17 | 2026-01-02 |
| Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension T4090 0.2%, T4090 0.3%, Rhopressa® - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Laboratoires Thea | 161 | 2024-08-05 | 2026-01-02 |
| Performance and Safety of T2769 in DED T2769, Vismed® Multi - Dry Eye | Not applicable | Completed | Laboratoires Thea | 251 | 2023-10-02 | 2026-01-23 |
| Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. T2769 - Dry Eye | Not applicable | Completed | Laboratoires Thea | 34 | 2023-08-15 | 2025-01-31 |
| Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses) Hydrocortisone, Dexamethasone, Povidone - Ocular Inflammation, Ocular Prostheses | Phase 3 | Recruiting | Agnes | 30 | 2023-05-12 | 2025-08-15 |
| Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers Bimatoprost Ophthalmic - Healthy Volunteers | Phase 1 | Completed | Laboratoires Thea | 40 | 2023-02-27 | 2023-11-14 |
| Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers T10070, Plastic tube with a roll-on applicator filled with an ointment - Healthy Volunteers | Not applicable | Completed | Laboratoires Thea | 39 | 2022-10-17 | 2022-12-07 |
| Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. Kinezodianone R hydrochloride, Placebo - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | Laboratoires Thea | 120 | 2022-07-05 | 2024-02-07 |
| Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients Bimatoprost Ophthalmic - Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratoires Thea | 684 | 2022-06-22 | 2024-07-18 |
Showing 20 of 73. Sign in to see all of them.
Dry Eye Syndromes (14) · Glaucoma (8) · Ocular Hypertension (7) · Retinal Diseases (7) · Vision Disorders (7) · Eye Abnormalities (6) · Eye Diseases, Hereditary (6) · Eye Diseases (5) · Eye Infections, Bacterial (5) · Retinitis Pigmentosa (5) · Usher Syndromes (5) · Eyelid Diseases (4) · Conjunctivitis, Allergic (3) · Glaucoma, Open-Angle (3) · Meckel Syndrome, Type 4 (3)
Azithromycin (8) · Intravitreal Injections (3) · Latanoprost (3) · Bimatoprost (2) · Cyclosporine (2) · Dietary Supplements (2) · Ophthalmic Solutions (2) · Povidone (2) · Prostaglandins (2) · Blood Specimen Collection (1) · Carticaine (1) · Dexamethasone (1) · Ganfort (1) · Hydrocortisone (1) · Mydriatics (1)
France (29) · United States (11) · United Kingdom (7) · Belgium (6) · Germany (6) · Bulgaria (4) · Canada (4) · Netherlands (3) · Spain (3) · Austria (2) · Brazil (2) · Denmark (2) · Italy (2) · Tunisia (2) · Australia (1)
Christophe Baudouin, Professor (2) · Carl Erb (1)
PMID 16958049, PMID 17585003, PMID 21078132, PMID 23150626, PMID 24937169, PMID 26531052, PMID 27310103, PMID 28973076, PMID 30559420, PMID 31215818, PMID 32126990, PMID 33620690, PMID 33795869, PMID 35379979, PMID 39310045, PMID 39432158, PMID 39509178, PMID 40339601
2009 (2), 2025 (2), 2008 (1), 2017 (1), 2018 (1), 2019 (1)